Cardiovasculaire Geneeskunde.nl

WCN 2010: Update on the prevention and treatment of thromboembolic disorders

Slides (presentatie) - Dec. 15, 2010

Bekijk de slides, klik op de afbeelding



Targets for anticoagulants

Overview: phase III clinical trials of new oral anticoagulants

Overview: phase III clinical trials of new oral anticoagulants

VKAs are more effective than antiplatelet therapy for stroke prevention

RE-LY: A Non-inferiority Trial

Stroke or Systemic Embolism

Ischaemic/Unspecified Stroke

Haemorrhagic Stroke

Bleeding and Myocardial Infarction

Dabigatran 150 mg vs. 110 mg

Common Adverse Events

Study Design

Primary Efficacy Outcome Stroke and non-CNS Embolism

Primary Efficacy Outcome Stroke and non-CNS Embolism

Key Secondary Efficacy Outcomes

Key Secondary Efficacy Outcomes

Time in Therapeutic Range (TTR) INR Data

Primary Efficacy Outcome by Quartiles of cTTR Stroke and non-CNS Embolism

Primary Safety Outcomes

Primary Safety Outcomes

Adverse Events and Liver Enzyme Data

Summary

Baseline patient demographics: comparison of ROCKET AF with previous VKA-controlled trials

Deze inhoud is bedoeld voor medische professionals. Om dit te bekijken is registratie noodzakelijk. Registreer gratis voor onbeperkte toegang tot ons educatief materiaal.

Deel deze pagina met collega's en vrienden: